Business
MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022
Results Highlight the Safety and Efficacy in Hard-to-Heal Wounds SAWC to Take Place in Phoenix, Arizona on April 6-10, 2022 YAVNE, Israel, March 29, 2022
About this update from Mediwound Ltd.
[{"type":"text","content":"Results Highlight the Safety and Efficacy in Hard-to-Heal Wounds SAWC to Take Place in Phoenix, Arizona on April 6-10, 2022 YAVNE, Israel, March 29, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced a poster and oral presentation of its EscharEx® clinical data at the 35th Symposium on Advanced Wound Care (SAWC) Spring Conference taking place in Phoenix, Arizona on April 6-10, 2022 (Home | SAWC Spring). The oral presentation, titled: “Introduction to EscharEx: An Innovative Enzymatic Solution for the Debridement of Hard to Heal Wounds,” will be moderated by Vickie R. Driver, DPM, MS, FACFAS FAAWC (University of Virginia and Inova Healthcare) and will feature, John C. Lantis, M.D. (Mount Sinai West Hospital and Icahn School of Medicine), Cyaandi R. Dove, DPM (Advanced Wound & Ankle Center, Las Vegas, and Robert J. Snyder, D.P.M., M.Sc. (Barry University), who will discuss results from recent clinical studies. The topics include: the importance of debridement in wound management, the preliminary efficacy and safety data from two well controlled clinical studies in patients with venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs), along with a case series from a clinical pharmacology study demonstrating EscharEx's fast and effective debriding activity accompanied with reduction in biofilm and bacterial load. In addition to the oral presentation, the Company will present an abstract poster, titled: “Results from an Ongoing Open Phase 2 Study Assessing the Safety, Efficacy and Pharmacological Effects of Bromelain-based Enzymatic Debridement on Biofilm, Microbial loads and Cytokines in patients with DFU and VLU.” The poster will present EscharEx phase 2 pharmacology study data of debridement efficacy while reducing biofilm and bacterial bioburden. “We are excited to have the opportunity to highlight EscharEx at the upcoming SAWC Spring conference and share the recent positive clinical data from our ongoing phase 2 clinical trials with the wound care community,” said Sharon Malka, Chief Executive Officer of MediWound. “It is a great opportunity to showcase EscharEx’s potential as a best-in-class, non-surgical debridement option for the millions of patients suffering from chronic ...